Previous studies have shown that anti-microtubule agents disrupt Golgi complexes in hepatocytes and other cells, causing breakdown or vesiculation of Golgi cisternal membranes. Whether this change in the structure of the Golgi membranes is associated with changes in Golgi membrane function is not known. The present study was initiated to investigate this issue; i.e., to determine whether anti-microtubule agents that cause structural changes in Golgi membranes in vivo would, at the same time, affect characteristic enzyme functions of Golgi membranes. To this end, colchicine was given to young rats in vivo and various hepatic subcellular membranes were subsequently isolated and utilized for enzyme assays. Initially it was shown that colchicine (2.5 mg/kg body wt.) given for 5 h significantly decreased the activities of the Golgi-membraneassociated enzymes galactosyl-, sialyl-and N-acetylglucosaminyl-transferases. More detailed experiments indicated that low doses of colchicine (0.8 mg/kg body wt.), although less effective than higher doses, decreased the activities of the terminal glycosylating enzymes maximally at 5 h, with partial and complete recovery at 12 and 24 h respectively. Treatment in vivo of rats with vinblastine (20mg/kg body wt.) for 5 h mimicked the action of colchicine. Two microsomal glycosylating enzymes (mannosyland N-acetylglucosaminyl-transferases) were unaffected by the treatment with colchicine, as were various hepatic 'marker' enzymes such as 5'-nucleotidase, glucose 6-phosphatase and succinate: 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium reductase (succinate dehydrogenase; EC 1.3.99.1), which were found to be enriched in plasma-membrane, endoplasmic-reticulum and mitochondrial-membrane fractions respectively. These results show that anti-microtubule agents specifically suppress the activity of Golgi-associated glycosyltransferases in liver. Although it seems likely that these changes are related to the previously observed structural changes in hepatocyte Golgi complexes after colchicine treatment, to what extent the results are linked to the interaction of colchicine with microtubule protein remains to be clarified.
It is well known that antimicrotubule agents block the release of secretory products in many different cell types (Obberghen et al., 1974; Stein et al., 1974; Kemper et al., 1975; LeMarchand et al., 1975; Poisner & Cooke, 1975; Redman et al., 1975; Banerjee et al., 1976; Williams, 1976; Reaven & Reaven, 1980) and that these products accumulate in the cells within vesicles derived from * To whom correspondence and reprint requests should be sent at Veterans Administration Medical Center (182B), 3801 Miranda Avenue, Palo Alto, CA 94304, U.S.A.
Golgi complexes. The prevailing view is that the block occurs at some site distal to the processing of the secretory product by the Golgi membranes (Banerjee et al., 1976) . It is noteworthy, however, that the structure of the Golgi complexes of many cells is itself extremely sensitive to the action of anti-microtubule drugs (Moskalewski et al., 1975; Seybold et al., 1975; Hindelang-Gertner et al., 1976;  first type of change involves the drug-induced topographical redistribution of Golgi complexes within the cytoplasm of cells (Moskalewski et al., 1975 (Moskalewski et al., , 1976 Hoffstein et al., 1977; Reaven & Reaven, 1977; DeBrabander et al., 1978; Knudson et al., 1978; Stock et al., 1978) . The second observed change involves the alteration of the most characteristic structural feature of Golgi complexes, their stacked cisternal membranes. After treatment of cells with colchicine, vinblastine or 2H20, the number of Golgi cisternal membranes per Golgi complex is found to be markedly reduced (Moskalewski et al., 1975 (Moskalewski et al., , 1976 Seybold et al., 1975; Hindelang-Gertner et al., 1976; Reaven & Reaven, 1980) ; indeed, our recent quantification of this phenomenon in hepatocytes suggests that approx. 80% of Golgi cisternal membranes are disrupted after treatment of animals with colchicine (Reaven & Reaven, 1980) .
Despite the frequency of these observations, it is not yet clear whether the drug-induced relocation of Golgi complexes or the 'disruption' or 'vesiculation' of Golgi cisternal membranes in any way alters the function of the Golgi complexes in cells. The Golgi apparatus is known to be a plastic changeable organelle with no uniform shape, and it is not certain what is its most active form; there are, in fact, well-documented instances where the stacked Golgi membranes are reduced in number (used up?) when the cells are in their most active stage of processing secretory products (Friedman & Cardell, 1977) .
Also, vesiculation of membranes (as may occur after treatment of tissues with anti-microtubule drugs) does not by itself imply loss of function, as is clear from the many enzyme studies that are routinely carried out on homogenized and sonicated preparations of membranes. On the other hand, one cannot be certain in any given instance that vesiculation of membranes is a benign event, and it is possible that certain Golgi-associated functions may be altered after the disruption of Golgi complexes with anti-microtubule drugs. Were this to be the case, one might reasonably question whether or not the anti-microtubule-drug-induced block in secretion was a function of improper processing of the secretory proteins (or their limiting membranes) by the affected Golgi structures.
The current study represents the first of several studies to examine this possibility; in particular, it seeks to determine if anti-microtubule agents, which seem to alter specifically the organization of Golgi membranes, also affect a specific function of these membranes. The primary objective of the study has been to determine the effect of colchicine and vinblastine administered in vivo on the activity in vitro of terminal glycosyltransferases (galactosyl-, N-acetylglucosaminyl-and sialyl-transferases) thought to be located exclusively in Golgi membranes (Bretz et al., 1980) . The decision to use an 'in vitro' approach was based on our desire to distinguish between drug-related glycosylation and secretory events, i.e., to exclude whatever effects a primary or secondary block in secretion might impose on the interpretation of the glycosylation data.
The results show that the concentration of anti-microtubule agents that induces ultrastructural changes in hepatocyte Golgi complexes also affects hepatic Golgi-associated terminal glycosyltransferases. In contrast, core glycosyltransferases and hepatic 'marker' enzymes associated with other non-Golgi membranes of liver cells are not affected. Groups of three male Sprague-Dawley rats (250-280g; Simonsen Laboratories, Gilroy, CA, U.S.A.) were injected intravenously under light diethyl ether anaesthesia with freshly prepared colchicine (usually 2.5 mg/kg body wt.) in normal saline (0.9% NaCl). Control groups of rats received an equal volume of normal saline. The animals had free access to water and, unless otherwise stated, were killed 5 h after colchicine injection.
Experimental procedures
The livers were quickly removed, placed in 0.25M-sucrose at 4°C and immediately processed for the isolation of'Golgi and smooth-and roughendoplasmic reticulum fractions by a slightly modified prodedure of Ehrenreich et al. (1973) and Bergeron et al. (1978) . The 105 000g pellet (referred to as 'starting microsomal fraction') was used as the source of the various Golgi fractions. The starting microsomal fraction was suspended in 6.5 ml of 0.25M-sucrose (equivalent to lOg of liver) and 8ml of 2M-sucrose was added to achieve a final sucrose concentration of 1.22M. A portion (14ml) of this fraction was subsequently overlayered with 8ml of 1.05 M-, 14 ml of 0.86 M-, 14 ml of 0.6 M-and 9.5 ml of 0.25M-sucrose solutions and the tubes were centrifuged in a Beckman SW 25.2 rotor at 76 900g,8, for 3 h. Three Golgi fractions, referred to as 'GF1' (light), 'GF2' (intermediate) and 'GF3' (heavy), were collected, diluted to 0.25 M-sucrose and resedimented at 105 000g for 1 h. All the fractions were resuspended in 1 ml of 0.25 M-sucrose and immediately assayed for enzyme activities or processed for electron microscopy. Similarly, the load fractions from the above gradients, which consist of microsomes, were diluted to 0.25 M-sucrose and further processed for the isolation of smooth and rough endoplasmic reticulum as described previously (Reaven & Azhar, 1981) .
Discontinuous-sucrose-density-gradient centrifugation of galactosyltransferase and other nonglycosylating enzymes Starting microsomal fraction (8 ml; sucrose concentration 1.22M) was subsequently overlayed with 5ml of 1.05M-, 8ml of 0.86M-, 8ml of 0.6M-and 6 ml of 0.25 M-sucrose solutions. Centrifugation was carried out at 104000g., in a Beckman SW 28.2 rotor for 3 h. At the end of centrifugation, 1 ml fractions were collected from the top of the tube (total 35 fractions) and each fraction was then assayed immediately for various marker enzymes. Isolation ofother liver subcellularfractions Rat liver plasma membranes and mitochondria were isolated as described previously (Reaven & Azhar, 1981) . Enzyme assays All assays were carried out under experimental conditions in which enzyme activity was linear with respect to enzyme protein concentration and incubation time.
Measurement of Golgi glycosyltransferases. Sialyltransferase. Activity was measured by the procedure of Bretz et al. (1980) . The samples were processed for radioactivity determination as described by Kim et al. (1971) .
Galactosyltransferase. Activity was assayed by the procedures of Bretz & Staubli (1977) and Bretz et al. (1980) . The incubation mixture in a final volume of 50,u1 contained 100mM-sodium cacodylate, pH 6.8, 50 mM-MnCl2, 40 mM-2-mercaptoethanol, 2mM-ATP, 0.4% Triton X-100, 17.5mg of ovomucoid/ml and 2.1 mM-UDP-['4CIgalactose (0.95 pCi/ml) and appropriate amounts of membrane fraction. After incubation at 37°C for 20min, the reaction was stopped by the addition of 3 ml of 1% (w/v) phosphotungstic acid in 0.5M-HCI. The samples were processsed for radioactivity determination as described by Kim et al. (1971) . In some instances N-acetylneuraminic acid-and galactosefree fetuin or N-acetylneuraminic acid-free mucin (17.5 mg/ml) instead of ovomucoid was used as acceptor protein. When N-acetyl-D-glucosamine (40mM) was used as acceptor, the product N-['4C lacetyl-lactosamine was separated by Dowex column chromatography (Morre, 1971) . N-Acetylglucosaminyltransferase. The incubation conditions of this enzyme were the same as those described by Bretz et al. (1980) . Transfer of radioactivity from UDP-N-['4Clacetyl-D-glucosamine to Smith-degraded ovomucoid (25 mg/ml; Bretz et al., 1980) or ovalbumin (28mg/ml; AmarCostesec, 1981) was determined as described by Kim et al. (1971) .
Measurement of transfer of core sugars to microsomes. N-Acetylglucosamine transfer. The incorporation of N-[3H]acetyl-D-glucosamine from UDP-N-[3Hlacetyl-D-glucosamine into total microsomal and smooth-and rough-endoplasmic-reticulum fractions was measured by a modification of the procedures of Heifetz & Elbein (1977) and Waechter & Harford (1977) .
Mannose transfer. Transfer of [14C Imannose from GDP-[14Clmannose into total microsomal and smooth-and rough-endoplasmic-reticulum fractions was measured by a modification of previously published procedures (Chambers & Elbein, 1975; Heifetz & Elbein, 1977; Waechter & Harford, 1977) .
Miscellaneous enzyme assays. 5 '-Nucleotidase and glucose 6-phosphatase activities were measured by the procedure of Aronson & Touster (1974) . Microchondrial succinate: 2-(p-iodophenyl)-3-(pnitrophenyl)-5-phenyltetrazolium reductase activity was measured by the procedure of Pennington (1961) .
Analytical methods
The protein concentration of each membrane fraction was measured by the technique of Lowry et al. (1951) as modified by Markwell et al. (1978) . P1 was quantified colorimetrically (Fiske & SubbaRow, 1925) .
Electron-microscopic procedures
Processing of membrane fractions. Immediately after isolation, portions of the various membrane fractions were fixed for 10min at 4°C in 1.5% glutaraldehyde prepared in O.1M-cacodylate buffer (pH 7.2; 420 mosM), and subsequently spun for 2min at 100lOOg in a microcentrifuge (Airfuge; Beckman Instruments, Palo Alto, CA, U.S.A.). The resulting pellets were left overnight in cold fixative, then processed by standard techniques (Reaven & Reaven, 1980; Reaven & Azhar, 1981 ) the next day. All preparations were examined electron microscopically to check for membrane purity.
Quantification of contaminating membranes within Golgi-membrane fractions. When suitably embedded, the pelleted Golgi membranes could be thin-sectioned through their entire thickness. Six electron micrographs (16000 x) were taken at random from one embedded block of each of such Vol. 212 Golgi-membrane specimens, and subjected to quantification as follows. Photographic prints (enlarged 3 x) were prepared from each micrograph and all vesicular profiles bounded by ribosomes were identified on each print. The percentage frequency of rough-surfaced profiles (containing very-low-density lipoprotein), among other smooth-membraned structures (containing very-low-density lipoproteins), was estimated by using stereological volume density techniques (Weibel, 1973) .
Results
Effect ofcolchicine on glycosyltransferase activity in Golgifractions Colchicine dose and treatment time on galactosylsialyland N-acetylglucosaminyl-transferase activities. In these studies two doses of colchicine were used; one (2.5 mg/kg body wt.) was known to be maximally effective after 5 h in decreasing verylow-density-lipoprotein secretion in liver, disrupting Golgi complexes and eliminating microtubules in hepatocytes (Reaven & Reaven, 1980) ; approx. 50% of the rats given this dose of colchicine died between 12 and 24 h. The second dose of colchicine (0.8 mg/kg body wt.) was equally effective in altering liver structure and function at 5 h, but partial recovery of these hepatocyte features was seen at 12 h and all processes, in all the animals studied, were normal by 24 h after treatment with the drug (Azhar & Reaven, 1982) . Given these results, it was of interest to see whether both doses of colchicine supplied in vivo had the same effect on terminal glycosyltransferases located in membranes of hepatic Golgi complexes. The results presented in Fig. 1 indicate that 0.8mg of colchicine/kg body wt. produced a 40-50% decrease in galactosyl-, sialyl-, and N-acetylglucosaminyl-transferase activities in GF1, GF2 and GF3 fractions. The effect was more marked in the case of sialyltransferase, with 50-70% decrease in all three Golgi fractions tested. Increasing the dose of colchicine to 2.5 mg/kg body wt. further decreased the activities of all three terminal glycosyltransferases, with an average decrease of 70-80% in Golgi fractions.
Administration of colchicine at a dose of 2.5 mg/ kg body wt. produced a linear decrease in activity of the transferases in total (pooled) Golgi fractions. The drug effect was evident as early as 1 h and the extent of inhibition increased with time up to 5 h, the maximum time point studied (results not shown). Insofar as the effect of colchicine on all three Golgi-associated glycosyltransferases was identical, subsequent experiments were simplified and results are provided for only one enzyme, galctosyltransferase.
Effect of colchicine on galactosyltransferase kinetics and acceptor specificity. To determine whether colchicine given in vivo (2.5mg/kg body wt.) altered the catalytic properties of galactosyltransferase, Golgi Electron micrographs ofliver GFJ fraction from saline-and colchicine-treated rats (x 60000) (a) Shows a representative sample of GF 1 from saline-treated animals. This fraction shows a variety of smooth-surfaced vacuoles, many of which are filled with very-low-density lipoproteins embedded in electron-dense matrix (arrowheads); (b) shows a sample of GF 1 from colchicine-treated (2.5 mg/kg body wt. 5 h before death) rats. In addition to the structures seen in (a), a certain number of lipoprotein-filled rough-endoplasmic-reticulum vacuoles are also seen (arrowheads); such vacuoles have also been found in intact liver after colchicine treatment (see Reaven & Reaven, 1980 galactose, MnCl2 and ovomucoid in any Golgi fraction. However, the Vmax of the enzyme was greatly decreased regardless of the acceptor used (see Table 1 ).
Purity of isolated Golgi-membrane fractions. Golgi-membrane fractions from all experiments conducted with 2.5mg of colchicine/kg body wt. were examined by electron microscopy. The various fractions from saline-treated rats were identical with those previously described from this laboratory (Reaven & Azhar, 1981) and many others (Ehrenreich et al., 1973; Bergeron et al., 1978) ; Plate 1(a) is representative of the GF1 fraction from control rats. In contrast, GF1, GF2 and, to a much lesser extent GF3 fractions from colchicine-treated animals showed some contamination with endoplasmic reticulum; a micrograph showing ribosome-studded membranes (rough endoplasmic reticulum) with lumenal lipoproteins from a GFI fraction of colchicine-treated animals is shown in Plate l(b) (see also Reaven & Reaven, 1980) . The level of such rough-endoplasmic-reticulum contamination was estimated on the GF1 fractions of all experiments by using quantitative microscopic techniques, and was found to vary from 7 to 15% of the fractions obtained from colchicine-treated rats.
Although this finding suggests that the GFI and GF2 fractions of colchicine-treated rats may be contaminated to some extent with elements of the rough endoplasmic reticulum (by virtue of their lumenal lipoproteins and lighter density), the extent of this 7-15% contamination cannot account for the extent of the decrease (70-80%) found in the activities of the various Golgi glycosyltransferases.
Reversal of inhibitory action of colchicine on galactosyltransferase activity. To determine if the decrease in hepatic Golgi glycosyltransferase activity observed after colchicine treatment was reversible with time, rats were injected with colchicine (0.8 mg/kg body wt.), killed 5, 12 and 24 hours later and hepatic Golgi membranes were isolated for enzyme assays. As shown in Fig. 2 , this dose of colchicine, though less effective than a higher (2.5 mg/kg body wt.) dose (see also Fig. 1 acceptors (N-acetylneuraminic acid-free mucin and ovomucoid). The results showed no effect of colchicine on galactosyltransferase activity in the total homogenate. To explore this issue further we examined galactosyltransferase activity in various subcellular fractions of liver. In Table 2 , the effect of colchicine on galactosyltransferase activity is shown for total homogenate, serum and every subfraction of liver. For each fraction, enzyme activity is expressed per g of liver and the percentage recovery in each specific fraction (compared with its content in total homogenate) is indicated. Likewise, the protein content of the identical fraction and its percentage recovery (compared with that in total homogenate) is given. As can be seen from the relative specific activity, there is no enrichment of enzyme activity in the nuclear/mitochondrial fraction of either saline-or colchicine-treated animals. On the other hand, enzyme enrichment does occur in the starting microsomal fraction of both groups of animals, and the percentage increase is less, after colchicine treatment. In both situations, the amount of enzyme activity in the cytosolic (soluble) fraction is negligible. Details of Golgi and microsomal fractions (which are derived from the starting microsomal material) are discussed below.
For fine-resolution of the starting microsomal material, identical amounts of these fractions were placed in discontinuous sucrose gradients, centrifuged for 3 h (104 000 ga) and ml fractions were collected from the top for enzyme assays. Fig. 3 shows the distribution of galactosyltransferase activity from saline-and colchicine-treated rats. Data from GF 1 (fractions 4-8), GF2 (fractions 12-16), GF3 (fractions 20-24) and microsomes (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) were pooled for additional calculations in Table 2 . In Fig. 3(a) , three peaks of enzyme activity can be identified, with GF1 containing the lowest and GF3 the highest level of activity in both groups of animals, though colchicine-treated animals show less activity at every point. The load zone (which represents the microsomal fraction) also contains significant amounts of activity. Fig. 3(b) shows that the protein obtained from the GF1 and GF2 peaks of colchicine-treated rats is more than that of the saline-treated controls. (Fig. 3c) of Golgi-associated galactosyltransferase activity between the saline-and colchicine-treated animals, but showing almost no differences among the various Golgi fractions within a given animal group. The pooled data for these fractions are shown in Table 2 . From Table 2 Golgi fractions. To determine whether other (non-glycosylating) enzymes were similarly affected, separate assays were carried out for the marker enzymes 5 '-nucleotidase (plasma membrane), glucose 6-phosphatase (rough and smooth endoplasmic reticulum) and succinate: 2-(p-iodophenyl)-3 -(p-nitrophenyl)-5 -phenyltetrazolium reductase (mitochondria). For this purpose, we used portions of the identical sucrose-densitygradient fractions obtained for the assessment of galactosyltransferase as in Fig. 3 . Marker enzymes were also assayed in purified plasma membranes, mitochondria, total microsomes and rough-and smooth-endoplasmic-reticulum fractions from the same liver homogenates of saline-and colchicineinjected rats used for quantification of galactosyltransferase activity. The results of these measurements are seen in Fig. 4 (Parodi & Leloir, 1979) . To determine whether the drug colchicine had a unique effect on Golgi enzymes, we injected animals with a second anti-microtubule agent (vinblastine; 20mg/kg body wt.) (Wilson et al., 1975; Na & Timasheff, 1980) and assayed for galactosyltransferase activity in various hepatic functions. Vinblastine, like colchicine, markedly reduced the activity of this enzyme in all Golgi fractions (results not shown).
Discussion
These various data show that anti-microtubule agents have a specific inhibitory effect on the activities of various Golgi-associated sugar transferases in liver. This conclusion follows from the information that colchicine and vinblastine (to the extent that it was tested) (1) affect only hepatic Golgi terminal glycosyltransferases and not endoplasmic-reticulum-associated transferases, (2) affect only the level of terminal glycosyltransferase activities, and not the distribution of the enzymes in various subcellular fractions of liver homogenate and (3) do not affect the distribution, or the activities, of a number of other (non-Golgi) hepatic enzymes.
The first of the above points is straightforward and requires little explanation. Hepatic Golgi fractions show substantial decreases in galactosyl-, sialyl-and N-acetylglucosaminyl-transferase activity 5 h after treatment with either a low or a high dose of colchicine, or vinblastine sulphate. In contrast, transfer of mannose or N-acetylglucosamine to microsomes (assayed from the microsomal fractions Table 3 . Effect ofcolchicine treatment on transfer ofcore sugar (N-acetylglucosamine) to microsomes Incubation mixtures (final volume, 0.4 ml) contained 30mM-Tris/HCI buffer (pH 7.4), lOmM-MnCI2, 2.5 mM-EDTA, 0.5% Triton X-100, 2 x 105 c.p.m. of UDP-[3HlGlcNAc, microsomal fractions (2-3mg of protein) and, where required, 20pg of dolichyl phosphate (suspended in Triton X-100 as described by Chen & Lennarz, 1977) . After incubation at 37°C for 15min, the radioactivity incorporated into various fractions was determined as described in the Experimental procedures section. noteworthy that when the drug is given in low doses (0.8 g/kg body wt.), the effect seen at 5 h is totally reversed by 24 h.
As straightforward as these statements are, there is always some concern when working with subcellular fractions that the action of a drug may be to alter the physical make-up of the affected cells, resulting in a shift of either membranes or enzymes into different subcellular fractions during the isolation procedure. This concern is particularly felt in the present study, since previous morphological studies indicated that the organization of the hepatocyte Golgi complex is altered by the use of anti-microtubule drugs. Thus, to determine if the loss of Golgi glycosyltransferase activity is due to a change in the cellular distribution of the enzyme after colchicine treatment, we monitored and kept track of the activity of these transferases in all cell fractions derived from the initial homogenate and, in addition, we examined 35 sequential (1 ml) fractions of the starting microsomal/Golgi material run in discontinuous sucrose gradients. The results unequivocally show that the colchicine-induced loss of Golgi-associated glycosyltransferase activity cannot Vol. 212 be explained by a shift in the distribution of the enzyme. The following points can be made from Table 2 and Fig. 3 , which display the complete 'book-keeping' done for one enzyme, galactosyltransferase. When considering the homogenate as the starting material, one sees no colchicineinduced loss of galactosyltransferase activity to either the cytosol or the nuclear/mitochondrial fraction, and only a marginal decrease in activity is apparent in the starting microsomal fraction. This latter is comprised of the Golgi fractions plus the endoplasmic reticulum and only the enzyme that is present in the Golgi fractions appears to be sensitive to colchicine (Table 2) . Since an endoplasmicreticulum-based galactosyltransferase has recently been shown to have characteristics different from that of the Golgi enzyme (Andersson & Eriksson, 1981) , it perhaps is not too surprising that a difference in colchicine sensitivity exists in the two fractions. Moreover, since the colchicine-sensitive Golgi-associated enzyme comprises such a small proportion of the enzyme found in the whole homogenate (<15%; Table 2), one would not expect a change to be apparent in the activity of the homogenate itself. This expectation is borne out by the results of Table 2 . In addition, when one considers a detailed accounting of the enzyme within the starting microsomal fraction (as in Fig. 3) , it can be seen that colchicine affects only the maximal activity and not the distribution pattern of galacto-syltransferase; i.e., enzyme activity is located in three peaks identified as Golgi fractions GF1, GF2 and GF3 in saline-treated animals and smaller enzyme peaks, in identical locations, are obtained from the samples of colchicine-treated rats, suggesting that the enzyme is decreased in activity in treated rats but sediments in the same location in the gradient.
That the Golgi fractions are not substantially contaminated with other membranes (in either group of animals) is shown by the fact that marker enzymes for plasma membranes, endoplasmic reticulum and mitochondria assayed along with galactosyltransferase (Fig. 4) are not enriched in the Golgi regions. In' this regard, the fact that we can discern a 7-15% contamination of rough-endoplasmic-reticulum vesicles by electron microscopy (Plate 1) in the GF1 fractions in the colchicinetreated rats, and not in the controls, gives cause for some concern. We have no reasonable explanation for our inability to measure equivalent changes in glucose 6-phosphatase in the membranes derived from the colchicine-treated animals, but insofar as these data have been confirmed by us many times, we must accept them. Perhaps those particular rough-endoplasmic-reticulum vesicles that are associated with secretory product no longer contain glucose 6-phosphatase. In any event, contamination of the magnitude displayed in the electron-microscopy samples cannot account for the colchicineinduced enzyme changes observed in the Golgi fractions.
At this point, the mechanism responsible for these Golgi-associated changes in galactosyltransferase activity is not understood, i.e., we do not know if colchicine reduces the enzyme content of the Golgi membranes or if enzyme activity that is present cannot be normally expressed. We are quite certain, however, that the specific decrease in galactosyltransferase activity is not due to drug inactivation of the enzyme during the prolonged isolation of the membranes, i.e., the homogenate and all subcellular fractions were assayed at the same time and were therefore equally exposed to colchicine, yet only the enzyme activity of the Golgi fractions was affected.
In all, the findings from the present study are consistent with morphological data that show that membranes of the Golgi samples are altered in vivo after the treatment of rats with colchicine or vinblastine under precisely the conditions used in the present study (Reaven & Reaven, 1980) . We believe these events are linked somehow, i.e., that antimicrotubule agents specifically interfere with membrane reconstruction in the Golgi region and that this, in turn, affects Golgi-associated enzymes such as the terminal glycotransferases. To what extentthese results are related to the interaction of the anti-microtubule drugs with hepatic microtubule protein remains to be clarified.
